This article was originally published on ETFTrends.com.
After languishing in the latter stages of 2018, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and the SPDR S&P Biotech ETF (NYSEArca: XBI) are sporting double-digit gains early in 2019. Some analysts see the potential for these biotech ETFs and other to lure more assets from investors. Healthcare [...]
Continue Reading Below